MEIP News and Press, MEI Pharma Inc. From 10/01/21

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the grant of inducement stock options for an aggregate of 136,000 shares of the company’s common stock to three new employees. The stock options wer...

MEI Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference PR Newswire SAN DIEGO , Sept. 22, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today ann...

The following slide deck was published by MEI Pharma, Inc. in conjunction with this event. For further details see: MEI Pharma (MEIP) Presents At 23rd Annual Global Investment Virtual Conference - Slideshow

The following slide deck was published by MEI Pharma, Inc. in conjunction with this event. For further details see: MEI Pharma (MEIP) presents at 2021 Wells Fargo Healthcare Virtual Conference

MEI Pharma, Inc. (MEIP) Q4 2021 Earnings Conference Call September 2, 2021 05:00 PM ET Company Participants David Walsey - Vice President, Investor Relations and Corporate Communications Brian Drazba - Chief Financial Officer Dan Gold - President and Chief Executive Officer Conference Call Pa...

MEI Pharma Reports Fiscal Year 2021 Results and Operational Highlights - Reporting of Topline TIDAL Study Data Expected in the Fourth Quarter of Calendar Year 2021 - - MEI Begins Fiscal Year 2022 with $153 Million in Cash - - Conference Call Today at 5:00 p.m. Eastern Ti...

MEI Pharma to Present at Two Healthcare Conferences PR Newswire SAN DIEGO , Sept. 2, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that it will present...

AVGO, COO, CTHR, CTLP, GWRE, HPE, MDB, MDLA, MEIP, PD, SAIC, YEXT For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Thursday's close

MEI Pharma to Release 2021 Fiscal Year End Financial Results and Provide Corporate Update on September 2, 2021 PR Newswire SAN DIEGO , Aug. 26, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing ne...

MEI Pharma and Kyowa Kirin Announce First Patient Dosed in the Phase 3 COASTAL Study Evaluating Zandelisib Plus Rituximab in Relapsed or Refractory Indolent Non Hodgkin's B-cell Lymphoma -COASTAL is intended to support FDA and global marketing approvals in patients with relapsed...